Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Chinese Patent Office
Queensland Health
Healthtrust
Chubb
Accenture
Medtronic
McKinsey
Colorcon

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,786,111

« Back to Dashboard

Summary for Patent: 7,786,111
Title:Medicaments for the treatment of chronic obstructive pulmonary disease
Abstract: A pharmaceutical composition comprising a compound of formula 1 ##STR00001## wherein: n is 1 or 2; R.sup.1 is hydrogen, C.sub.1-C.sub.4-alkyl, halogen, OH, or --O--C.sub.1-C.sub.4-alkyl; R.sup.2 is hydrogen, C.sub.1-C.sub.4-alkyl, halogen, OH, or --O--C.sub.1-C.sub.4-alkyl; R.sup.3 is hydrogen, C.sub.1-C.sub.4-alkyl, OH, halogen, --O--C.sub.1-C.sub.4-alkyl, --O--C.sub.1-C.sub.4-alkylene-COOH, or --O--C.sub.1-C.sub.4-alkylene-CO--O--C.sub.1-C.sub.4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).
Inventor(s): Konetzki; Ingo (Warthausen, DE), Schromm; Kurt (Ingelheim, DE), Schollenberger; Hermann (Ingelheim, DE), Pestel; Sabine (Attenweiler, DE), Schnapp; Andreas (Biberach, DE), Bouyssou; Thierry (Warthausen, DE), Buettner; Frank (Attenweiler, DE), Heine; Claudia (Biberach, DE), Rudolf; Klaus (Warthausen, DE), Lustenberger; Philipp (Basel, CH), Hoenke; Christoph (Ingelheim, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:12/258,830
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Delivery;

Drugs Protected by US Patent 7,786,111

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim STIOLTO RESPIMAT olodaterol hydrochloride; tiotropium bromide SPRAY, METERED;INHALATION 206756-001 May 21, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Boehringer Ingelheim STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108-001 Jul 31, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,786,111

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 53 282Nov 15, 2002

Non-Orange Book US Patents Family Members for Patent 7,786,111

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,056,916 Medicaments for the treatment of chronic obstructive pulmonary disease ➤ Sign Up
8,044,046 Medicaments for the treatment of chronic obstructive pulmonary disease ➤ Sign Up
7,727,984 Medicaments for the treatment of chronic obstructive pulmonary disease ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
QuintilesIMS
Chinese Patent Office
Medtronic
Federal Trade Commission
Merck
UBS
Mallinckrodt
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.